Human immunodeficiency virus (HIV)-positive patients are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV)-positive participants; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS); appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Participants known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated; screening for HIV infection at baseline is not required
Medical history:\r\n* History of intracranial abscess within  months prior to start of study therapy\r\n* Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)\r\n* NOTE: HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with nivolumab\r\n* Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated\r\n* History of allergy to study drug components\r\n* History of severe hypersensitivity reaction to any monoclonal antibody;
Participants with a known history of human immunodeficiency virus (HIV) are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV)-positive participants; HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV)-positive participants are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV)-positive participants are ineligible; appropriate studies will be undertaken in HIV-positive participants when indicated.
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with apalutamide and abiraterone. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
Patients who are known human immunodeficiency virus (HIV), hepatitis B or hepatitis C positive; HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated; HIV, hepatitis B and hepatitis C testing is not required for patients not known to have those infections
Participants known to be human immunodeficiency virus (HIV)-positive and on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Patients are excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS); appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed)\r\n* HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV) infection: HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS); HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness (HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with oral THU-Dec; appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated
Subjects who are human immunodeficiency virus (HIV)-positive will be excluded from the study\r\n* Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated; also include whether HIV testing is required for this study, or only if a known diagnosis will be excluded
Human immunodeficiency virus (HIV) positive (+) with a cluster of differentiation (CD) count <  are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated; HIV testing prior to enrollment is not required for screening but strongly encouraged for patients with no documented prior HIV assessment
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; HIV-positive patients with cluster of differentiation (CD)+ =< /mm^ are ineligible; appropriate studies will be undertaken in this group of patients when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy known to interact with CYP isoenzymes are ineligible; in addition, HIV patients with CD count <  cells/uL are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness (HIV-positive subjects on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated
Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human Immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated
Patients with known human immunodeficiency virus (HIV) are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with zolpidem; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
